questionsmedicales.fr
Acides nucléiques, nucléotides et nucléosides
Nucléotides
Ribonucléotides
Nucléoside diphosphate ose
Adénosine diphosphate ose
Adénosine diphosphate ribose
O-acétyl-ADP-ribose
O-acétyl-ADP-ribose : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Analyse Chromatographique
Spectrométrie de Masse
Tests Biochimiques
Dosage Enzymatique
Échantillons Sanguins
Méthodes de Mesure
Biomarqueurs
Niveaux Biologiques
Dysfonctionnement Cellulaire
Troubles Métaboliques
Symptômes
5
Douleur
Troubles Inflammatoires
Troubles Neurologiques
Études Cliniques
Symptômes Digestifs
Déséquilibres Métaboliques
Système Immunitaire
Réponse Immunitaire
Prévention
5
Mode de Vie Sain
Prévention des Maladies
Exercice Physique
Métabolisme
Suppléments
Consultation Médicale
Traitements
5
Inhibiteurs Enzymatiques
Modulateurs Métaboliques
Médicaments
Voies Métaboliques
Thérapies Alternatives
Suppléments Nutritionnels
Alimentation Équilibrée
Régulation Métabolique
Interventions Chirurgicales
Complications Médicales
Complications
5
Complications Métaboliques
Inflammation
Maladies Chroniques
Diabète
Troubles Cardiovasculaires
Études Épidémiologiques
Santé Mentale
Troubles Associés
Infections
Système Immunitaire
Facteurs de risque
5
Facteurs de Risque
Mode de Vie
Vieillissement
Santé Cellulaire
Mode de Vie Sédentaire
Déséquilibres Métaboliques
Maladies Préexistantes
Diabète
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "O-acétyl-ADP-ribose : Questions médicales les plus fréquentes",
"headline": "O-acétyl-ADP-ribose : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les O-acétyl-ADP-ribose : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-08",
"dateModified": "2025-03-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "O-acétyl-ADP-ribose"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Adénosine diphosphate ribose",
"url": "https://questionsmedicales.fr/mesh/D000246",
"about": {
"@type": "MedicalCondition",
"name": "Adénosine diphosphate ribose",
"code": {
"@type": "MedicalCode",
"code": "D000246",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D13.695.827.708.070.125"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "O-acétyl-ADP-ribose",
"alternateName": "O-Acetyl-ADP-Ribose",
"code": {
"@type": "MedicalCode",
"code": "D038961",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Anthony K L Leung",
"url": "https://questionsmedicales.fr/author/Anthony%20K%20L%20Leung",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA."
}
},
{
"@type": "Person",
"name": "Morgan Dasovich",
"url": "https://questionsmedicales.fr/author/Morgan%20Dasovich",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA."
}
},
{
"@type": "Person",
"name": "Mohsen Badiee",
"url": "https://questionsmedicales.fr/author/Mohsen%20Badiee",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205."
}
},
{
"@type": "Person",
"name": "Yong Zhang",
"url": "https://questionsmedicales.fr/author/Yong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States."
}
},
{
"@type": "Person",
"name": "Sua Myong",
"url": "https://questionsmedicales.fr/author/Sua%20Myong",
"affiliation": {
"@type": "Organization",
"name": "Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.",
"datePublished": "2022-07-19",
"url": "https://questionsmedicales.fr/article/35878575",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.nicl.2022.103109"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37473734",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000532022"
}
},
{
"@type": "ScholarlyArticle",
"name": "Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development - (III) A Randomized Trial with Interferon Beta-1a Products.",
"datePublished": "2022-12-02",
"url": "https://questionsmedicales.fr/article/36324229",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cpt.2784"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.",
"datePublished": "2023-06-07",
"url": "https://questionsmedicales.fr/article/37273189",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/17425247.2023.2221432"
}
},
{
"@type": "ScholarlyArticle",
"name": "Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis.",
"datePublished": "2022-07-14",
"url": "https://questionsmedicales.fr/article/35853357",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jneuroim.2022.577932"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides nucléiques, nucléotides et nucléosides",
"item": "https://questionsmedicales.fr/mesh/D009706"
},
{
"@type": "ListItem",
"position": 3,
"name": "Nucléotides",
"item": "https://questionsmedicales.fr/mesh/D009711"
},
{
"@type": "ListItem",
"position": 4,
"name": "Ribonucléotides",
"item": "https://questionsmedicales.fr/mesh/D012265"
},
{
"@type": "ListItem",
"position": 5,
"name": "Nucléoside diphosphate ose",
"item": "https://questionsmedicales.fr/mesh/D009702"
},
{
"@type": "ListItem",
"position": 6,
"name": "Adénosine diphosphate ose",
"item": "https://questionsmedicales.fr/mesh/D000247"
},
{
"@type": "ListItem",
"position": 7,
"name": "Adénosine diphosphate ribose",
"item": "https://questionsmedicales.fr/mesh/D000246"
},
{
"@type": "ListItem",
"position": 8,
"name": "O-acétyl-ADP-ribose",
"item": "https://questionsmedicales.fr/mesh/D038961"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : O-acétyl-ADP-ribose - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur O-acétyl-ADP-ribose",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur O-acétyl-ADP-ribose",
"description": "Comment détecter l'O-acétyl-ADP-ribose dans les cellules ?\nQuels tests sont utilisés pour évaluer l'O-acétyl-ADP-ribose ?\nL'O-acétyl-ADP-ribose est-il mesurable dans le sang ?\nY a-t-il des biomarqueurs associés à l'O-acétyl-ADP-ribose ?\nQuels sont les indicateurs de dysfonctionnement de l'O-acétyl-ADP-ribose ?",
"url": "https://questionsmedicales.fr/mesh/D038961?mesh_terms=Interferon+beta-1a#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur O-acétyl-ADP-ribose",
"description": "Quels symptômes sont liés à des niveaux anormaux d'O-acétyl-ADP-ribose ?\nL'O-acétyl-ADP-ribose provoque-t-il des douleurs ?\nY a-t-il des symptômes neurologiques liés à l'O-acétyl-ADP-ribose ?\nDes symptômes digestifs peuvent-ils être liés à l'O-acétyl-ADP-ribose ?\nL'O-acétyl-ADP-ribose affecte-t-il le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D038961?mesh_terms=Interferon+beta-1a#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur O-acétyl-ADP-ribose",
"description": "Comment prévenir les déséquilibres d'O-acétyl-ADP-ribose ?\nY a-t-il des recommandations diététiques pour l'O-acétyl-ADP-ribose ?\nL'exercice physique aide-t-il à réguler l'O-acétyl-ADP-ribose ?\nLe stress influence-t-il l'O-acétyl-ADP-ribose ?\nDes suppléments peuvent-ils prévenir les déséquilibres d'O-acétyl-ADP-ribose ?",
"url": "https://questionsmedicales.fr/mesh/D038961?mesh_terms=Interferon+beta-1a#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur O-acétyl-ADP-ribose",
"description": "Quels traitements ciblent l'O-acétyl-ADP-ribose ?\nL'O-acétyl-ADP-ribose peut-il être traité par des médicaments ?\nY a-t-il des thérapies alternatives pour l'O-acétyl-ADP-ribose ?\nComment l'alimentation influence-t-elle l'O-acétyl-ADP-ribose ?\nDes interventions chirurgicales sont-elles nécessaires pour l'O-acétyl-ADP-ribose ?",
"url": "https://questionsmedicales.fr/mesh/D038961?mesh_terms=Interferon+beta-1a#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur O-acétyl-ADP-ribose",
"description": "Quelles complications peuvent survenir avec l'O-acétyl-ADP-ribose ?\nL'O-acétyl-ADP-ribose est-il lié à des maladies chroniques ?\nDes troubles cardiovasculaires peuvent-ils être liés à l'O-acétyl-ADP-ribose ?\nL'O-acétyl-ADP-ribose peut-il affecter la santé mentale ?\nY a-t-il des risques d'infection liés à l'O-acétyl-ADP-ribose ?",
"url": "https://questionsmedicales.fr/mesh/D038961?mesh_terms=Interferon+beta-1a#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur O-acétyl-ADP-ribose",
"description": "Quels facteurs de risque influencent l'O-acétyl-ADP-ribose ?\nL'âge est-il un facteur de risque pour l'O-acétyl-ADP-ribose ?\nLe tabagisme influence-t-il l'O-acétyl-ADP-ribose ?\nLe manque d'exercice est-il un facteur de risque ?\nDes maladies préexistantes augmentent-elles le risque d'O-acétyl-ADP-ribose ?",
"url": "https://questionsmedicales.fr/mesh/D038961?mesh_terms=Interferon+beta-1a#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment détecter l'O-acétyl-ADP-ribose dans les cellules ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques comme la chromatographie et la spectrométrie de masse sont utilisées."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'O-acétyl-ADP-ribose ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests biochimiques et les dosages enzymatiques sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "L'O-acétyl-ADP-ribose est-il mesurable dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être mesuré dans des échantillons sanguins par des méthodes spécifiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à l'O-acétyl-ADP-ribose ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biomarqueurs spécifiques peuvent indiquer des niveaux d'O-acétyl-ADP-ribose."
}
},
{
"@type": "Question",
"name": "Quels sont les indicateurs de dysfonctionnement de l'O-acétyl-ADP-ribose ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux peuvent indiquer des troubles métaboliques ou cellulaires."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à des niveaux anormaux d'O-acétyl-ADP-ribose ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés peuvent inclure fatigue, troubles métaboliques et inflammation."
}
},
{
"@type": "Question",
"name": "L'O-acétyl-ADP-ribose provoque-t-il des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être associé à des douleurs dues à des troubles métaboliques ou inflammatoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques liés à l'O-acétyl-ADP-ribose ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien potentiel avec des troubles neurologiques, mais c'est encore à explorer."
}
},
{
"@type": "Question",
"name": "Des symptômes digestifs peuvent-ils être liés à l'O-acétyl-ADP-ribose ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des déséquilibres métaboliques peuvent entraîner des symptômes digestifs."
}
},
{
"@type": "Question",
"name": "L'O-acétyl-ADP-ribose affecte-t-il le système immunitaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut influencer la réponse immunitaire, entraînant des symptômes d'inflammation."
}
},
{
"@type": "Question",
"name": "Comment prévenir les déséquilibres d'O-acétyl-ADP-ribose ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain et équilibré peut aider à prévenir ces déséquilibres."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations diététiques pour l'O-acétyl-ADP-ribose ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants et nutriments peut soutenir la santé cellulaire."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à réguler l'O-acétyl-ADP-ribose ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer le métabolisme et réguler les niveaux d'O-acétyl-ADP-ribose."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il l'O-acétyl-ADP-ribose ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut perturber les niveaux d'O-acétyl-ADP-ribose et affecter la santé."
}
},
{
"@type": "Question",
"name": "Des suppléments peuvent-ils prévenir les déséquilibres d'O-acétyl-ADP-ribose ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains suppléments peuvent aider, mais il est essentiel de consulter un professionnel de santé."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent l'O-acétyl-ADP-ribose ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs enzymatiques et des modulateurs métaboliques sont explorés comme traitements."
}
},
{
"@type": "Question",
"name": "L'O-acétyl-ADP-ribose peut-il être traité par des médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours pour développer des médicaments ciblant ses voies métaboliques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies alternatives pour l'O-acétyl-ADP-ribose ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies alternatives, comme les suppléments, sont étudiées mais nécessitent plus de preuves."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation influence-t-elle l'O-acétyl-ADP-ribose ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut aider à réguler les niveaux d'O-acétyl-ADP-ribose."
}
},
{
"@type": "Question",
"name": "Des interventions chirurgicales sont-elles nécessaires pour l'O-acétyl-ADP-ribose ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "En général, les interventions chirurgicales ne sont pas nécessaires, sauf en cas de complications graves."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'O-acétyl-ADP-ribose ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications métaboliques et inflammatoires peuvent survenir en cas de déséquilibre."
}
},
{
"@type": "Question",
"name": "L'O-acétyl-ADP-ribose est-il lié à des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux anormaux peuvent être associés à des maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Des troubles cardiovasculaires peuvent-ils être liés à l'O-acétyl-ADP-ribose ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien potentiel entre les déséquilibres et les troubles cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'O-acétyl-ADP-ribose peut-il affecter la santé mentale ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches indiquent qu'il pourrait influencer la santé mentale et les troubles associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'infection liés à l'O-acétyl-ADP-ribose ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des déséquilibres peuvent affaiblir le système immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque influencent l'O-acétyl-ADP-ribose ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'alimentation, le stress et le mode de vie peuvent influencer ses niveaux."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour l'O-acétyl-ADP-ribose ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter les niveaux d'O-acétyl-ADP-ribose et la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il l'O-acétyl-ADP-ribose ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut perturber le métabolisme et affecter les niveaux d'O-acétyl-ADP-ribose."
}
},
{
"@type": "Question",
"name": "Le manque d'exercice est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire peut contribuer à des déséquilibres d'O-acétyl-ADP-ribose."
}
},
{
"@type": "Question",
"name": "Des maladies préexistantes augmentent-elles le risque d'O-acétyl-ADP-ribose ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies, comme le diabète, peuvent augmenter le risque de déséquilibres."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 03/03/2025
Contenu vérifié selon les dernières recommandations médicales
10 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
5 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Department of Chemistry, Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218, USA.
Publications dans "O-acétyl-ADP-ribose" :
5 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205.
Publications dans "O-acétyl-ADP-ribose" :
4 publications dans cette catégorie
Affiliations :
Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.
Department of Chemistry, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, California 90089, United States.
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089, United States.
Research Center for Liver Diseases, University of Southern California, Los Angeles, California 90089, United States.
Publications dans "O-acétyl-ADP-ribose" :
4 publications dans cette catégorie
Affiliations :
Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States.
Department of Biophysics, Johns Hopkins University, Baltimore, Maryland 21218, United States.
Physics Frontier Center (Center for the Physics of Living Cells), University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Affiliations :
Department of Biomedical Sciences, Chung Shan Medical University, Taichung, Taiwan.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Affiliations :
Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Affiliations :
Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Affiliations :
Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Affiliations :
Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Affiliations :
Department of Food Science and Biotechnology, Da-Yeh University, Changhua, Taiwan.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Affiliations :
Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan.
Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.
Department of Food Science and Biotechnology, Da-Yeh University, Changhua, Taiwan.
Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
Guang EM Laboratory, New Taipei, Taiwan.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Affiliations :
Laboratory of Signaling and Gene Regulation, Cecil H. and Ida Green Center for Reproductive Biology Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Section of Laboratory Research, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: Cristel.Camacho@utsouthwestern.edu.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Affiliations :
Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Affiliations :
Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Affiliations :
Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA.
Publications dans "O-acétyl-ADP-ribose" :
3 publications dans cette catégorie
Publications dans "O-acétyl-ADP-ribose" :
2 publications dans cette catégorie
Affiliations :
Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan.
Publications dans "O-acétyl-ADP-ribose" :
2 publications dans cette catégorie
Affiliations :
Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan.
Publications dans "O-acétyl-ADP-ribose" :
2 publications dans cette catégorie
Affiliations :
Molecular Toxicology Group, University of Konstanz, Konstanz, Germany.
Publications dans "O-acétyl-ADP-ribose" :
Myelin water imaging is a magnetic resonance imaging (MRI) technique that quantifies myelin damage and repair in multiple sclerosis (MS) via the myelin water fraction (MWF)....
In this substudy of a phase 3 therapeutic trial, OPERA II, MWF was assessed in relapsing MS participants assigned to interferon beta-1a (IFNb-1a) or ocrelizumab (OCR) during a two-year double-blind pe...
MWF in normal appearing white matter (NAWM), including both whole brain NAWM and 5 white matter structures, and chronic lesions, was assessed in 29 OCR and 26 IFNb-1a treated participants at weeks 0, ...
Linear mixed-effects models of data from baseline to week 96 showed a difference in the change in MWF over time favouring ocrelizumab in all NAWM regions. At week 192, lesion MWF was lower for partici...
Ocrelizumab appears to protect against demyelination in MS NAWM and chronic lesions and may allow for a more permissive micro environment for remyelination to occur in focal and diffusely damaged tiss...
Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously be...
Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as t...
A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Chan...
Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight int...
The US Food and Drug Administration (FDA) has taken steps to bring efficiency to the development of biosimilars, including establishing guidance for the use of pharmacokinetic and pharmacodynamic (PD)...
Self-administration of subcutaneous interferon beta-1a (sc IFN β-1a) can be achieved with the RebiSmart® electromechanical autoinjector. This study investigated adherence to, and duration of persisten...
This retrospective, observational study utilized data from RebiSmart® devices, recorded on the MSdialog database, between January 2014 and November 2019. Adherence and persistence were evaluated over ...
The population of RebiSmart® users (...
People living with MS were highly adherent to use of the RebiSmart® device, with higher persistence generally observed for older and/or male individuals....
A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif™) develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We hypothesized t...
A 62-year-old woman with a history of multiple sclerosis (MS) presented with recurrent episodes of confusion, dysarthria and gait difficulties. These episodes occurred about 3 days after administratio...
Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disorder. Elevated levels of pro-inflammatory mediators and some oxidative stress parameters can accelerate the demyelination proce...
Eighty RRMS patients were equally divided into 2 groups: the intervention group receiving IFNβ-1a plus 2 gm of metformin once daily and the control group receiving IFNβ-1a alone. Interleukin 17 (IL17)...
At baseline, there were no statistically significant differences between the two groups (p > 0.05). After 6 months, the change in the median (interquartile range) of the results for both the intervent...
Adding metformin to IFNβ-1a demonstrated a potential effect on an oxidative stress marker (MDA). However, there is no statistically significant effect on immunological, MRI and clinical outcomes. We r...
ClinicalTrials.gov number: NCT05298670, 28/3/2022....
Interferon (IFN)-β-1a (Avonex) and longer half-life, polyethylene glycol-conjugated IFN-β-1a (PEG-IFN-β-1a, Plegridy), may generate different molecular responses. We identified different short-term an...
With few approved multiple sclerosis therapies in the pediatric population, there is a need for further approved treatment options. Limited data exist for dimethyl fumarate (DMF) treatment in pediatri...
To compare the efficacy, safety, and tolerability of DMF vs intramuscular interferon β-1a (IFNβ-1a) in POMS....
The CONNECT study was an active-controlled, open-label, rater-blinded 96-week randomized clinical trial in patients with POMS aged 10 to less than 18 years treated between August 2014 and November 202...
Patients were randomized to DMF or IFNβ-1a....
The primary end point was the proportion of patients free of new or newly enlarging (N or NE) T2 hyperintense lesions at week 96 among trial completers. Secondary end points included number of N or NE...
Among 150 patients with POMS in the intention-to-treat (ITT) population (median [range] age, 15 [10-17] years; 101 [67.3%] female patients), 78 individuals received DMF and 72 individuals received IFN...
This study found that more pediatric patients with POMS treated with DMF were free of new or newly enlarging T2 lesions and that the adjusted ARR was lower among these patients compared with those tre...
ClinicalTrials.gov Identifier: NCT02283853....
Interferon beta therapies are well-established disease-modifying treatments for patients with relapsing multiple sclerosis (MS). Based on clinical evidence from two large cohort studies, both, the EMA...
The post-authorisation safety study PRIMA included adult women diagnosed with relapsing-remitting MS or clinically isolated syndrome, who were treated with peginterferon beta-1a or IM interferon beta-...
In total, 426 women were enrolled, reporting 542 pregnancies that resulted in 466 live births. A total of 162 women completed the questionnaire for 192 live births (53.1% male). Newborns had Apgar sco...
Study results confirmed former reports indicating that exposure to interferon beta therapies during pregnancy or lactation had no adverse effects on intrauterine growth and child development over the ...
NCT04655222, EUPAS38347....